These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15134981)

  • 1. Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging.
    Nishiyama T; Tomita Y; Takahashi K
    Urology; 2004 May; 63(5):917-21. PubMed ID: 15134981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
    Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
    Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
    Ohlson N; Bergh A; Nygren K; Stattin P; Wikström P
    Eur Urol; 2006 Apr; 49(4):675-83. PubMed ID: 16387414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS; Roehrborn CG; Wolford E; Wilson TH
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of prostate gland volume with and without androgen deprivation after intensity modulated radiotherapy - A follow-up study.
    Zechmann CM; Aftab K; Didinger B; Giesel FL; Zamecnik P; Thieke C; Fütterer JJ; Kopp-Schneider A; Kauczor HU; Delorme S
    Radiother Oncol; 2009 Mar; 90(3):408-12. PubMed ID: 18950882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
    Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
    Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T; Hashimoto Y; Takahashi K
    Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?
    Berthelet E; Pickles T; Truong PT; Liu M; Pai HH; Kwan WB; Lim JT;
    Can J Urol; 2007 Aug; 14(4):3621-7. PubMed ID: 17784982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.